Pfizer’s customer map: wholesalers, governments, and what investors need to know

Pfizer monetizes by developing and commercializing branded medicines and vaccines and selling them through a mix of large wholesalers, retailers, integrated delivery systems and government purchasers. Revenue flows are concentrated through a small number of U.S. wholesalers while government contracts remain strategically important for vaccines and pandemic-era products, creating a business model that blends long-term supply agreements with routine short-term trade relationships. For investors and operators evaluating counterparty exposure, the interplay of concentration, contract length and counterparty type drives credit risk, working capital dynamics and negotiating leverage.

Explore more on customer risk and counterparty intelligence at https://nullexposure.com/ to see how these relationships affect credit and financing decisions.

Quick thesis: how customer structure defines risk and leverage

Pfizer’s distribution and revenue profile gives the company scale and predictable channels for its core products while concentrating operational and credit exposure in a few counterparties. Wholesalers like McKesson, Cencora and Cardinal Health capture a large share of product flows and receivables, strengthening Pfizer’s distribution reach but increasing counterparty concentration risk. Simultaneously, historic government procurement (notably for COVID-19 vaccines and antivirals) reduced after the transition of key products to commercial markets, altering revenue seasonality and receivables composition. These dynamics shape Pfizer’s contracting posture: a mix of multi-year supply agreements for strategic products and short-term credit sales for normal trade.

The four customer relationships you must track

Below are the customer relationships Pfizer discloses as material in its FY2024 Form 10‑K. Each entry includes a concise plain-English takeaway and the source.

McKesson, Inc.

McKesson accounted for 23% of Pfizer’s total revenues in 2024, up from 16% in 2023 and 8% in 2022, underlining its role as the largest U.S. wholesaler customer. According to Pfizer’s 2024 Form 10‑K, McKesson is a primary distribution channel through which a large portion of prescription biopharmaceutical sales flow (Pfizer FY2024 10‑K).

Cencora, Inc.

Cencora represented 17% of total revenues in 2024, rising from 12% in 2023 and 5% in 2022, reflecting rapid growth in purchases as Pfizer’s product mix transitioned post-pandemic. Pfizer’s FY2024 10‑K lists Cencora among the three largest U.S. wholesalers that channel a substantial share of sales and receivables (Pfizer FY2024 10‑K).

Cardinal Health, Inc.

Cardinal Health accounted for 14% of total revenues in 2024, up from 10% in 2023 and 4% in 2022, making it the third major wholesaler in Pfizer’s U.S. distribution footprint. Pfizer’s disclosure in the FY2024 10‑K highlights Cardinal Health as one of the core wholesalers concentrating volume and receivables (Pfizer FY2024 10‑K).

U.S. government

The U.S. government represented 6% of total revenues in 2024, a sharp decline from 23% in 2022, driven by the transition of Comirnaty and Paxlovid from government procurement to commercial markets. Pfizer’s FY2024 10‑K attributes the decrease in government revenue share to that commercial transition while noting continued direct government sales for certain vaccines and pandemic-response inventories (Pfizer FY2024 10‑K).

What these relationships tell you about Pfizer’s operating model

• Contracting posture is mixed. Pfizer combines long-term, multi-year supply agreements for strategic vaccines (explicitly documented for Comirnaty with the European Commission through 2026) with short-term credit sales for routine pharmaceutical commerce. This hybrid posture lowers product-delivery risk for key programs while preserving flexible trading terms for day-to-day sales.
• Concentration is high and measurable. Collectively, Pfizer’s three largest U.S. wholesalers represent a substantial share of revenue and constituted 34% of total trade accounts receivable at December 31, 2024 (and 42% at year-end 2023), concentrating credit exposure in a few large counterparties.
• Counterparty criticality varies by product. Government purchasers were critical during the pandemic for Paxlovid and Comirnaty; as these products transitioned to commercial markets, government share of revenue fell materially. Wholesalers, by contrast, are critical for distribution and working capital because sizeable receivables are due from them.
• Geography and maturity. Pfizer operates globally—supplying approximately 200 countries and territories—while the U.S. remains the single country contributing more than 10% of total revenue in recent years, anchoring near-term commercial risk and regulatory exposure.
• Materiality signal is nuanced. Accounts receivable from the U.S. government were disclosed as not material to consolidated financial statements at year‑end 2024, even as wholesale receivables remain material to Pfizer’s trade receivables composition. Treat government receivables and wholesale receivables differently when modeling credit loss and recovery scenarios.

Why these dynamics matter for premium finance and credit decisions

For investors and providers of receivables finance, Pfizer’s profile presents both strengths and structural cautions. Strengths include scale, diversified product portfolio and explicit long-term supply agreements for priority vaccines, which support predictable cash flows on strategic programs. Cautions include heavy receivable concentration among a few wholesalers and shifting government demand for vaccines, which can amplify working capital cycles and negotiating leverage on price and payment terms.

If underwriting receivables or structuring credit facilities, prioritize:

• counterparty-level credit assessment of McKesson, Cencora and Cardinal Health,
• covenant language that reflects concentration limits and aging thresholds,
• stress tests that incorporate the commercial transition of previously government‑procured products.

Learn more about how to map customer concentration into financing structures at https://nullexposure.com/.

Final read: tactical monitoring and investor actions

• Monitor quarterly 10‑K/10‑Q disclosures for changes in the percentage of revenue sourced from the three wholesalers and updates on long-term supply amendments for Comirnaty and other priority programs. Pfizer’s FY2024 10‑K provides the baseline percentages and narrative on the government transition.
• Treat government and wholesaler receivables differently in models: government receivables are low counterparty-risk but can be episodic and policy-driven; wholesaler receivables are commercial, recurring and concentrated.
• Reassess concentration limits after material product transitions, such as the migration of pandemic products from government procurements to commercial channels, which reshapes receivables and pricing pressure.

For a detailed operational mapping of counterparty exposure and to evaluate tailored financing approaches, visit https://nullexposure.com/ and connect with our analysis team.

Bold takeaway: Pfizer’s distribution model delivers global scale but concentrates credit exposure in a few large U.S. wholesalers; combine counterparty credit checks with contract-term analysis to price risk correctly.